ArcBest resumed with an Overweight at Stephens
Stephens resumed coverage of ArcBest with an Overweight rating and $205 price target. The transport cycle is broadly improving, with more fundamental upside potential than downside risk ahead, its momentum should carry well into 2027, and "investors should capitalize rising earnings at historically elevated multiples,"